[Lotus]

[attachment=5254]Maybe this can help give some clarity how Hrt works.

[SarahSchilling]

LOL, why do I feel like this is aimed at me?

Anyways, looks to be about what I thought. First visit labs, if those are ok...second visit scripts.

I just wonder what the view on progestorone and prolactin will be....and how exactly the fact that I'm already on hormones changes things.

I guess I'll find out soon. I just hope he doesn't make me go a month without em.....if so I guess I'd eat hops and peony root if allowed for a month lol

At least then my cranky ass would be sedated.

[Lotus]

Ha!, more hops, lol,

What do you think he would say when you show him you already have breasts? I'd like to be a fly on the wall at that point.

Maybe skip a step or two? I hope he's not a schmuck!

[SarahSchilling]

Ha!, more hops, lol,

What do you think he would say when you show him you already have breasts? I'd like to be a fly on the wall at that point.

Maybe skip a step or two? I hope he's not a schmuck!

LOL, i don't have boobs! Not sure why you guys think I do.

If I did, though...it'd be easily explained by my admittance of taking hormones for about 7 months already, and the lab results.
Of course, the PM for a year before that was more effective for me in growing breasts...but I can't be sure that's not just because my thyroid got worse after that. Besides, I don't think a doctor would believe that herbs do anything.
Guessing the labs won't be in the female range, but probably not in the male one either lol

[Lotus]

I thought this should be shared with the group, try not to get hung up or be offended by some of the terminology, rather focus on the study and how it shows reduced mortality rates, check it out....

Long-term cross-sex hormone treatment is safe in transsexual subjects


In April 2011, the European Journal of Endocrinology published an important paper in scientific literature dealing with transsexual subjects. The authors presented mortality data on 966 male-to-female (MtF) and 365 female-to-male (FtM) transsexual subjects who had undergone long-term standard cross-sex hormonal treatment. They concluded that in MtF subjects, mortality increases when compared to the general male and female population. The study showed that this increased mortality is mainly due to non-hormonal causes; suicide, AIDS and illicit drug related deaths were higher when compared to the general population.

Transsexualism is a rare condition affecting approximately one in 12,000 males and one in 30,000 females and collecting data from more than 1000 patients treated within the same medical center is remarkable. Compared to other papers dealing with this topic, this article appears particularly relevant considering both the sample size and the length of follow-up. Data on mortality rates in transsexual subjects undergoing cross-sex hormone treatment with or without SRS are scanty. Asscheman and colleagues are not new to this research having reported the effects of hormonal treatment in 1989 and 1997 and, since then, findings from this group have confirmed that increased mortality in these subjects is not due to hormonal causes. The length of follow-up is also remarkable since it was suggested in a previous report that mortality rate differences start to appear after 10 years. In this paper, over 90% of the subjects were followed for more than 10 years with a median time of 18 years.

The full study:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720111/

---

European Journal of Endocrinology.

HTML Full version.
http://www.eje-online.org/content/164/4/...994a62fa69

PDF Full version
http://www.eje-online.org/content/164/4/635.full.pdf



Denita

---

European Journal of Endocrinology.

HTML Full version.
http://www.eje-online.org/content/164/4/...994a62fa69

PDF Full version
http://www.eje-online.org/content/164/4/635.full.pdf



Denita

Thanks Denita,

Those links are more detailed (big help), it's nice to find a report of this size that gives a clear view:

Compared to other papers dealing with this topic, this article appears particularly relevant considering both the sample size and the length of follow-up. Data on mortality rates in transsexual subjects undergoing cross-sex hormone treatment with or without SRS are scanty.